Impedimed Limited (AU:IPD)
ASX:IPD
Want to see AU:IPD full AI Analyst Report?
IPD Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume149.09K
Average Volume (3M)853.05K
Market Cap
AU$30.58M
Enterprise ValueAU$31.63M
Total Cash (Recent Filing)AU$18.85M
Total Debt (Recent Filing)AU$21.93M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,038,747,700
10 Day Avg. Volume551,953
30 Day Avg. Volume853,052
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.45
Price to Sales (P/S)5.55
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.05Price Target Upside137.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$16.48M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained gross margin of ~86% indicates the BIS device business has high structural product-level profitability and pricing power versus direct costs. That margin buffer supports reinvestment in sales, clinical validation and product development over the next 2–6 months.
Consistent Revenue GrowthRevenue growth (reported 10.23% year and fundamentals showing higher-period growth) points to expanding adoption of BIS devices. Persistent top-line momentum supports installed-base expansion and recurring consumable or software revenue that can compound over several quarters.
Manageable LeverageA debt-to-equity around 0.71 implies conservative borrowing relative to equity, leaving financial flexibility to fund clinical studies, go-to-market investments or capital needs without immediate refinancing pressure over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows and a deteriorating FCF growth rate (-20.73%) signal structural cash burn. This constrains ability to self-fund commercialization or R&D and increases reliance on external financing over the coming months.
Weak Overall ProfitabilityNegative EBIT and net margins show that operating expenses and overhead absorb gross profits. Unless operating leverage improves, profitability will remain weak, limiting free cash flow conversion and shareholder returns over the medium term.
Negative Return On EquityA negative ROE indicates the company is not currently generating returns on shareholder capital, reflecting operational losses and capital inefficiency. This structural issue can hinder investor confidence and raise capital costs for necessary future funding.
Impedimed Limited News
IPD FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is AU$30.58M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 124 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of -AU$0.002 by -AU$0.004.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate is 0.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 2,038,747,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of -AU$0.002. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in AU:IPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.05 (137.50% Upside)
AU$0.05 (137.50% Upside)
Blogger Sentiment
Bullish
AU:IPD Sentiment 88%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$29.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
-165.13%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Impedimed Limited
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
IPD Stock 12 Month Forecast
Average Price Target
AU$0.05
▲(137.50% Upside)
Technical Analysis
Compumedics Limited
―
Uscom Limited
―
HeraMED Ltd.
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---